CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
9-cis-Retinoic Aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001504
NCT00001504Phase 1Completed
CompareCT.gov

A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients

National Cancer Institute (NCI)·interventional·Posted Nov 4, 1999·Updated Mar 4, 2008

In Brief

A Phase 1 clinical trial evaluating 9-cis-Retinoic Acid for Breast Cancer and Breast Neoplasm. Completed, across 1 site.

Detailed Summary

This is a dosage escalation study to estimate the maximum tolerated dose of 9-cis-retinoic acid given in combination with tamoxifen. Groups of 3 to 6 patients receive oral 9-cis-retinoic acid daily for 4 weeks, after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Breast Neoplasm
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 1999
Enrollment StartMay 1, 1996
Study CompletionJan 1, 2002
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

9-cis-Retinoic Aciddrug